

# ANNOUNCEMENT 2019



## WHO Collaborating Centre for Research and Training in Management of Multidrug-Resistant Tuberculosis, Latvia

The WHO Collaborating Centre for Research and Training in Management of MDR-TB (WHO CC) in Riga, Latvia was established in 2004 with the objective of providing high quality, evidence-based capacity development at all levels (individual, organizational and institutional), drawing on worldwide evidence and in line with the latest developments and WHO guidance. Capacity development activities are structured according to the latest scientific developments in practical aspects of the treatment and management of drug-resistant tuberculosis (DR-TB).

TIME	COURSE	LANGUAGE	REGISTRATION DEADLINE
28/01 - 01/02	Latest updates in management of TB in children	RUSSIAN	<b>closed</b>
11/03 20/03	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	ENGLISH	<b>01/02</b>
08/04 17/04	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	RUSSIAN	<b>01/03</b>
13/05 17/05	Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB <hr/> Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB	RUSSIAN	<b>03/04</b>
03/06 12/06	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	RUSSIAN	<b>03/05</b>
19/08 28/08	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	RUSSIAN	<b>07/07</b>
21/10 25/10	Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB <hr/> Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB	RUSSIAN	<b>10/09</b>

Upon request, different types of capacity development activities are designed and organised for TB laboratory management, adjuvant surgery for TB, childhood TB, effective health communication and training of trainers.



[www.tblatvia.com](http://www.tblatvia.com)

**COURSE DIRECTOR: Dr. Liga Kuksa**

**COURSE COORDINATORS: Ms. Liga Rusmane, Ms. Ita Sprukule**



[liga.kuksa@aslimnica.lv](mailto:liga.kuksa@aslimnica.lv)


















[liga.rusmane@aslimnica.lv](mailto:liga.rusmane@aslimnica.lv)



## Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals

### COURSE MODULES:

-  Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants, migrants and other vulnerable groups
-  WHO's End TB Strategy and roadmap to implement TB action plan for the European Region, 2016-2020
-  Perspectives of the NTP's on implementing innovative diagnostics and treatment for MDR-TB
-  Updates on diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI)
-  Designing an effective regimen using clinical case scenarios from the field
-  Updates on treatment of drug-susceptible TB and patient care
-  Active drug safety monitoring and management (aDSM)
-  Use of shorter MDR-TB regimens in European regions; the ethical imperative to move to shorter regimens
-  Treatment of MDR-TB in special situations, TB/HIV co-infection
-  Adjuvant therapies in M/XDR-TB management: nutrition, surgery, rehabilitation
-  Fundamentals of infection control; FAST: a TB infection control strategy
-  Management of failures and chronic patients the role of palliative care
-  Developing models of care for MDR-TB patients; people-centered TB care
-  Monitoring of treatment effectiveness and outcome evaluation for TB and MDR-TB patients
-  Procurement and supply management (PSM)



### TARGET AUDIENCE:

Clinicians, staff of national TB programs, persons responsible for diagnostics and treatment of DR-TB, from countries with high levels of DR-TB



### DURATION:

9 business days (from Monday to Wednesday, including Saturday)



### LANGUAGE:

Russian/English



### TRAINING FEE:

1700 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support.

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.



## Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB

### COURSE MODULES:

- ❖ Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants.
- ❖ Perspectives of the National Tuberculosis Program (NTP) on implementing innovative diagnostics and treatment for M/XDR-TB.
- ❖ Laboratory diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI).
- ❖ Programmatic approach to the treatment of rifampicin-resistant TB (RR-TB); the role of clinicians in the introduction of new and repurposed drugs and regimens for different types of resistance.
- ❖ Clinical issues in new drug introduction, regimen design, and drug-drug interactions; off-label use of new TB drugs; use in special populations.
- ❖ Role of patient-centred care, support and adherence-support package; ethical considerations and informed consent; examples of patient consent.
- ❖ Adjuvant therapies; the role of surgery using new and re-purposed drugs.
- ❖ Drug safety; scope of safety data collection and definitions; active drug safety monitoring and management (aDSM).
- ❖ Clinical management of adverse events of interest: peripheral neuropathy, myelosuppression, prolonged QT interval, optic nerve disorder (optic neuritis), hepatitis, acute kidney injury, hearing impairment, hypokalemia, and hypothyroidism.
- ❖ Monitoring and evaluation requirements for the use of new and re-purposed drugs; length of therapy with new drugs.
- ❖ Pharmacokinetic and minimum inhibitory concentration (MIC) variability as determinants of TB clinical outcomes in adults and children - state of the evidence.

### TARGET AUDIENCE:

Clinicians, staff of national TB programs, persons responsible for diagnostics and treatment of DR-TB, from countries with high levels of DR-TB

### DURATION:

5 business days (from Monday to Friday)

### LANGUAGE:

Russian

### TRAINING FEE:

1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support











Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.



## Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB

*This hands-on work training was designed by combining the latest evidence and recommendations on rapid molecular diagnostic methods with practical work at the TB Supranational Reference Laboratory in Riga, Latvia*

### COURSE MODULES:

-  Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV. Social determinants, migrants and other vulnerable groups.
-  Development of DR-TB epidemic on crossroads. Can we prevent development and spread of DR-TB?
-  National Tuberculosis Program (NTP) perspectives on implementing innovative diagnostics and treatment for MDR-TB.
-  Updates on diagnosis of TB and TB drug resistance. Proposed TB diagnostic algorithm by the European TB Laboratory Initiative (ELI).
-  Using of shorter MDR-TB regimens in Europe regions.
-  TB Laboratory services and laboratory network.
-  Molecular line probe assays for the detection of mutations associated with resistance to first and second line TB drugs.
-  Internal and external quality control at different diagnostic methods.
-  Infection control requirement for laboratories at different levels.
-  Drug susceptibility testing for Delamanid and Bedaquiline (Linezolid).



#### TARGET AUDIENCE:

TB Laboratory specialists



#### DURATION:

5 business days (from Monday to Friday)



#### LANGUAGE:

Russian



#### TRAINING FEE:












1280 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.



## Latest updates in management of TB in children

### COURSE MODULES:

-  Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants, migrants and other vulnerable groups
-  Epidemiology of TB in children. Pathogenesis and peculiarities of childhood TB
-  WHO's End TB Strategy and roadmap to implement TB action plan for the European Region, 2016-2020
-  Updates on diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI)
-  Strategic approach to preventing and managing TB in children
-  Prophylaxis of TB in children, immunological diagnosis of TB infection diagnosis of TB in children
-  Diagnosis and treatment of TB /MDR/XDR TB in children
-  Developing models of care for TB in children; people-centered TB care, including ethical issues, human rights, and treatment in hospital or outpatient settings
-  Treatment of MDR-TB in special situations
-  Clinical management of drug adverse events
-  Active drug safety monitoring and management (aDSM)



#### TARGET AUDIENCE:

Pediatricians, TB specialists



#### DURATION:

5 business days (from Monday to Friday)



#### LANGUAGE:

Russian



#### TRAINING FEE:

1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.

WHO Collaborating Centre for Research and Training in Management of MDR-TB



[www.tblatvia.com](http://www.tblatvia.com)